Overview
The upstream switch for the entire reproductive hormone axis. Serious academic trials have examined it for fertility treatment and for sexual desire disorders in both sexes, which is more than most peptides here can claim.
Investigational — not approvedInvestigational only.
| Regulatory status | Investigational. Studied in academic reproductive endocrinology trials, notably at Imperial College London. Not approved. |
|---|---|
| Drug class | Decapeptide fragment of kisspeptin, the master regulator of GnRH release |
| Route | Intravenous or subcutaneous (research) |
| Half-life | Very short — minutes |
| Evidence rating |
3/5 Moderate
Evidence rating 3 out of 5: Moderate
Small or early-phase human trials, or good controlled topical human data. |
| Studied in | Trials as a trigger for oocyte maturation in IVF (reducing ovarian hyperstimulation risk), and randomized crossover trials in men and women with hypoactive sexual desire disorder. |
How it works
Binds KISS1R (GPR54) on hypothalamic GnRH neurons, triggering GnRH release and downstream LH and FSH secretion. Also has direct effects on limbic brain regions processing sexual and emotional stimuli, independent of the hormonal cascade.
Evidence base
Rated 3 of 5 — Moderate. Small or early-phase human trials, or good controlled topical human data.
- Real academic randomized trials, but early-phase and in narrow contexts.
Benefits & potential uses
Bars indicate how well each claim is supported: three = strong human evidence, two = moderate, one = preliminary or preclinical.
-
Safer IVF trigger Moderate evidence
Studied as an alternative to hCG for triggering oocyte maturation, with a lower risk of ovarian hyperstimulation syndrome — a genuinely dangerous complication.
-
Sexual desire effects in randomized trials Moderate evidence
Crossover trials in men and women with HSDD showed enhanced limbic responses to sexual stimuli and improved sexual response measures.
-
Physiological upstream mechanism Moderate evidence
Acts at the top of the reproductive axis, preserving downstream pulsatility and feedback.
-
Good short-term tolerability Moderate evidence
Academic trials reported minimal adverse effects with acute dosing.
Risks, cons & cautions
Bars indicate seriousness: three = serious or common, two = moderate, one = minor.
-
Not approved Serious
No regulatory authorisation for any indication.
-
Very short half-life Moderate evidence
Requires infusion or frequent dosing; practical delivery remains a barrier.
-
Receptor desensitisation with continuous exposure Moderate evidence
Sustained stimulation suppresses rather than stimulates the axis — the same paradox seen with GnRH agonists.
-
Reproductive axis manipulation Serious
Effects on menstrual cycles, fertility and hormone balance with chronic non-supervised use are unstudied.
-
Grey-market sale Serious
Sold as a research peptide for libido, well outside the trial contexts that generated the data.
Who should avoid it
- Hormone-sensitive cancers
- Pregnancy
- Unsupervised use for libido
If used under medical supervision, monitor
- LH, FSH, sex hormones if used clinically
- Menstrual cycle tracking
Regulatory & legal status
Investigational only.
Infographic
Where to read further
We link to live literature searches rather than a frozen citation list, so you always see current results — including anything published after our last review.
- PubMed — all published literature on Kisspeptin-10
- PubMed — randomized controlled trials only
- ClinicalTrials.gov — registered human trials
Related peptides in Hormonal & Reproductive
Terms used on this page
- Sexual Desire vs Arousal
- Sexual desire is the motivational interest in sexual activity while arousal is the genital and subjective response to stimulation, and the two dissociate enough that trials measure them separately.
- Kisspeptin
- Kisspeptin is a hypothalamic neuropeptide, the product of the KISS1 gene, that acts on the receptor KISS1R to drive GnRH release and serves as the gatekeeper of puberty and fertility.
- Gonadotropin-Releasing Hormone (GnRH)
- Gonadotropin-releasing hormone is a hypothalamic decapeptide that travels the pituitary portal circulation to trigger LH and FSH release, sitting at the top of the reproductive axis.
- Hypothalamic-Pituitary-Gonadal (HPG) Axis
- The hypothalamic-pituitary-gonadal axis is the GnRH to gonadotropin to gonadal steroid loop that governs puberty, fertility and sex steroid production in both sexes.
- Pulsatile vs Tonic Signalling
- Pulsatile signalling delivers a hormone in discrete bursts whose frequency and amplitude carry the message, while tonic signalling exposes the receptor continuously, and the two can produce opposite effects.
- Agonist
- An agonist is a ligand that binds a receptor and stabilises its active conformation, producing a biological response rather than merely occupying the binding site.
This page is educational information, not medical advice. It cannot account for your medical history, medications, or risk factors. Do not start, stop or change any treatment based on it. Speak to a qualified healthcare professional who knows your case.